Rheumatoid ArthritisPhase 4NCT01219933
A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)
A Phase 4 study testing methylprednisolone and tocilizumab [RoActemra/Actemra] in people with Rheumatoid Arthritis, run by Hoffmann-La Roche at 16 sites in Belgium.
Trial summary
This open-label, single-arm study will assess the use of glucocorticoids (GC) in daily clinical practice and will evaluate the dose reduction of glucocorticoids once low disease activity is achieved in patients with rheumatoid arthritis tre ated with GC and background RoActemra/Actemra (tocilizumab) 8mg/kg… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Rheumatoid Arthritis
- What is being tested?
- methylprednisolone and tocilizumab [RoActemra/Actemra]
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 68 participants
- Where
- 16 sitesBelgium
- Study dates
- Jan 2011to Mar 2013
- Phase
- Phase 4
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Non-interventional phase
- Adult patients, >/=18 years of age
- Moderate to severe active rheumatoid arthritis defined as Disease Activity Score using 28-joint count (DAS28) >/=5.1
- Patients with inadequate clinical response to a current treatment with 2 or more non-biologic disease-modifying anti-rheumatic drugs (DMARDs), one of them being methotrexate (MTX) optimally administered during a period of more than 3 months or inadequate response to a current anti-TNF therapy
- Current use of oral glucocorticoids started at least 4 weeks prior to enrolment Interventional phase
- Patients enrolled in the non-interventional phase
- Patients with low disease activity defined as DAS28 </=3.2 at Visit 2
- Use of oral glucocorticoids with methylprednisolone equivalent dose of >/=1mg and </=20mg/day at Visit 2
Who cannot join
- Non-interventional \& interventional phase
- Rheumatic autoimmune disease other than rheumatoid arthritis, or significant systemic involvement secondary to rheumatoid arthritis
- Functional class IV as defined by the American College of Rheumatology (ACR) Classification of Functional Status in rheumatoid arthritis
- Prior history or current inflammatory joint disease other than rheumatoid arthritis (e.g. gout)
Trial locations and contacts
16 sites in 1 country.
16 sites in 1 country
Belgium16 sites
Study site
Aalst, 9300
Study site
Bruges, 8000
Study site
Brussels, 1020
Study site
Brussels, 1070
Study site
Charleroi, 6000
Study site
Edegem, 2650
Study site
Genk, 3600
Study site
Gilly, 6060
Study site
Godinne, 5530
Study site
Haine-Saint-Paul, 7100
Study site
Heusy, 4802
Study site
Kortrijk, 8500
Study site
La Louvière, 7100
Study site
Liège, 4000
Study site
Ostend, 8400
Study site
Wilrijk, 2610
About this study
Official title: An Open-label, Single-arm Study to Describe Glucocorticoid Use in Rheumatoid Arthritis Patients Treated With Tocilizumab in Daily Clinical Practice and to Evaluate Systematic Glucocorticoid Dose Reduction Once Low Disease Activity is Reached (ACT-ALONE)
This open-label, single-arm study will assess the use of glucocorticoids (GC) in daily clinical practice and will evaluate the dose reduction of glucocorticoids once low disease activity is achieved in patients with rheumatoid arthritis tre ated with GC and background RoActemra/Actemra (tocilizumab) 8mg/kg intravenously every 4 weeks. In the non-interventional phase, the use of GC in daily clinical Belgian practice will be evaluated and described. This period of maximum 6 mont hs will allow those patients to obtain the inclusion criteria for the secondary interventional phase. In the interventional phase, a systematic GC dose reductio n schedule will be evaluated in patients having achieved low disease activity wh ile receiving the same background therapy with RoActemra/Actemra 8 mg/kg. Methyl prednisolone will be given from a starting dose of >/= 1 mg to </=20 mg orally d aily and will be tapered down. The anticipated study duration is up to 13 months
- Conditions
- Rheumatoid Arthritis
- Being tested
- methylprednisolone, tocilizumab [RoActemra/Actemra]
- Medical subject headings
- Arthritis, Rheumatoid
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
starting dose >/= 1 mg and </= 20 mg orally daily, according to dose-reduction schedule
tocilizumab [RoActemra/Actemra]Drug
background therapy: 8 mg/kg iv every 4 weeks
| Study group | Role | What they receive |
|---|---|---|
| 1 | Experimental | Not described Receives: Drug: methylprednisolone; Drug: tocilizumab [RoActemra/Actemra] |
What is being measured
The primary outcome is the main question the study is designed to answer.
Median GC Dose Taken During the Noninterventional Phase
During the noninterventional phase of the study participants received GC as prescribed by the physician. Doses of all GC administered are expressed as MP equivalents.
Measured: V1 and V2 (up to 6 months after V1)
Number of Participants With GC Switches During the Noninterventional Phase
During the noninterventional phase of the study, once LDA was achieved, GC was switched to MP tablets.
Measured: V1 and V2 (up to 6 months after V1)
Type of GC Taken at the End of the Noninterventional Phase
During the noninterventional phase of the study participants received GC as prescribed by the physician.
Measured: V1 and V2 (up to 6 months after V1)
Percentage of Participants in the Interventional Phase Who Achieved LDA and Discontinued Oral GC Within 20 Weeks
The percentage of participants with rheumatoid arthritis (RA) with LDA was defined as DAS28 ≤3.2, able to discontinue oral GC within 20 weeks and at the latest at V8, confirmed at the Consolidation Visit without loss of clinical response defined as DAS28 (CRP) >3.2.
Measured: Visits 3 (7 months), 4 (8 months), 5 (9 months), 6 (10 months), 7 (11 months), and 8 (12 months)
Secondary outcomes (29)
Percentage of Participants Able to Acheive LDA Assessed Using DAS28 While Receiving Oral GC on Background Tocilizumab Treatment During the Noninterventional Phase
DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the CRP and Patient's Global Assessment (PtGA) of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 ≤3.2 and oral GC intake with MP equivalent dose of ≥1 mg and ≤20 mg/day= LDA.
Measured: V1 and V2 (up to 6 months after V1)
Percentage of Participants Acheiving Remission Assessed Using DAS28 While Receiving Oral GC on Background TocilizumabTreatment During the Noninterventional Phase
DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the CRP and PtGA of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 <2.6 = remission.
Measured: V1 and V2 (up to 6 months after V1)
Percentage of Participants With Erosions During the NonInterventional Phase
In RA, the presence, number and size of bone erosions and the number of joints with erosions on conventional radiographs (CRs) are hallmarks for diagnosis, staging and prediction of damage progression and are used for treatment monitoring in randomized controlled studies.
Measured: V1 and V2 (up to 6 months after V1)
Number of Erosions During the NonInterventional Phase
In RA, the presence, number, and size of bone erosions and the number of joints with erosions on CRs are hallmarks for diagnosis, staging and prediction of damage progression and are used for treatment monitoring in randomized controlled studies.
Measured: V1 and V2 (up to 6 months after V1)
Percentage of Participants Positive for Rheumatoid Factor (RF) During the Noninterventional Phase
RF is the auto antibody directed against immunoglobulin G (IgG) and its concentration is observed in human serum or plasma. RF value higher than 20 units per milliliter (U/mL) is considered positive.
Measured: V1 and V2 (up to 6 months after V1)
Percentage of Participants Positive for Anti-cyclic Citrullinated Peptide (Anti-CCP) Antibody During the Noninterventional Phase
Anti-CCP antibodies are important markers of bone erosion in RA. Anti-CCP antibodies were classified as positive if >7 U/mL.
Measured: V1 and V2 (up to 6 months after V1)
Health Assessment Questionnaire Disability Index (HAQ-DI) During the Noninterventional Phase
HAQ-DI is a self-reported, valid assessment of functional disability in RA. Assessed based on ability of participants to perform daily activities in 8 categories: dressing, arising, eating, walking, reaching, gripping, hygiene, and carrying out daily activities. HAQ-DI score range: 0-3: without any difficulty=0, with some difficulty=1, with much difficulty=2, unable to do=3. HAQ total scores expressed as overall mean score with range 0-3: 0-0.25=normal functioning; 0.25-0.5=mild functional limitation; 0.5-1=moderate functional limitation; more than 1=significant functional limitation. Timepoint was V2, or before V2 for participants withdrawn before V2.
Measured: V1 and V2 (up to 6 months after V1)
DAS28-CRP During the Noninterventional Phase
DAS28-CRP was calculated from the swollen joint count (SJC) and tender joint count (TJC) using the 28-joint count and CRP (mg/L). Total score range: 0 to 10, higher score indicated more disease activity. DAS28-CRP ≤3.2=LDA and >3.2 to 5.1=moderate to high disease activity, and DAS28-CRP <2.6=remission. Timepoint was V2, or before V2 for participants withdrawn before V2; DAS28-CRP values indicated in the Case Report Form (CRF) were recalculated by the data manager. The recalculated values were used in the statistical analyses.
Measured: V1 and V2 (up to 6 months after V1)
DAS28-ESR During the Noninterventional Phase
DAS28-ESR was calculated from the SJC and TJC using the 28 joints count and ESR (millimeters per hour [mm/hr]). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-ESR ≤3.2=LDA and >3.2 to 5.1=moderate to high disease activity, and DAS28-ESR <2.6=remission. Timepoint was V2, or before V2 for participants withdrawn before V2; DAS28-ESR values indicated in the CRF were recalculated by the data manager. The recalculated values were used in the statistical analyses.
Measured: V1 and V2 (up to 6 months after V1)
Clinical Disease Activity Index (CDAI) During the Noninterventional Phase
The CDAI is the numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGA and Physician Global Assessment (PGA) of disease assessed on 0-100 mm Visual analog scale (VAS); higher scores=greater affection due to disease activity. CDAI total score=0-76. CDAI ≤2.8=disease remission, >2.8 to 10=LDA, >10 to 22=moderate disease activity, and >22=high disease activity.
Measured: V1 and V2 (up to 6 months after V1)
Median Time Interval Between V1 and V2
The noninterventional phase was planned to last for a maximum of 6 months per participant. The time between V1 and V2 was measured in months.
Measured: V1 and V2 (up to 6 months after V1)
Median Dose of Tocilizumab During the Noninterventional Phase
Measured: V1 and V2 (up to 6 months after V1)
Number of Participants With Changes in Tocilizumab Dose During the Noninterventional Phase
The dose of tocilizumab could have been reduced from the recommended 8 mg/kg to 4 mg/kg in participants in the case of adverse events.
Measured: V1 and V2 (up to 6 months after V1)
Percentage of Participants With Changes in RA Treatment During the Noninterventional Phase
Measured: V1 and V2 (up to 6 months after V1)
Percentage of Participants Able to Start the GC Reduction Phase at V3
All participants who maintained LDA (defined as DAS28-CRP ≤3.2) from V2 to V3 were included in the interventional phase for reduction of GC.
Measured: V3 (7 months)
Percentage of Participants Able to Reduce Oral GCs by ≥50 Percent (%) During the Interventional Phase by V9
Measured: V9 (24 weeks after V3)
Percentage of Participants Able to Discontinue GCs During the Interventional Phase by V9
Measured: V9 (24 weeks after V3)
Time-Averaged GC Dose Changes During the Interventional Phase
Area Under the Curve (AUC) of GC dose during the interventional phase was determined using the trapezoidal method and was calculated as:
AUC = sigma(Ti+1 - Ti) x [(Di+1+Di)/2]
With Di=dosage at time Ti
It corresponds to the total GC dose received between Baseline (visit 3) and visit 9 and has been calculated only for the 30 patients achieving visit 9.
Measured: V3 (7 months) and CV (4 weeks after GC-free status, maximum of 24 weeks after V3)
DAS28-CRP During the Interventional Phase
DAS28-CRP was calculated from the SJC and TJC using the 28-joint count and CRP (mg/L). Total score range: 0 to 10, higher score indicated more disease activity. DAS28-CRP) ≤3.2=LDA and >3.2 to 5.1=moderate to high disease activity, and DAS28-CRP <2.6=remission. DAS28-CRP values indicated in the CRF were recalculated by the data manager. The cumulative DAS28 (CRP) value (AUC method) was performed using the calculated DAS28. The recalculated values were used in the statistical analyses.
Measured: V3 (7 months) and CV (4 weeks after GC-free status, maximum of 24 weeks after V3)
HAQ-DI During the Interventional Phase
HAQ-DI is a self-reported, valid assessment of functional disability in RA. Assessed based on ability of participants to perform daily activities in 8 categories: dressing, arising, eating, walking, reaching, gripping, hygiene, and carrying out daily activities. HAQ-DI score range: 0-3: without any difficulty=0, with some difficulty=1, with much difficulty=2, unable to do=3. HAQ total scores expressed as overall mean score with range 0-3: 0-0.25=normal functioning; 0.25-0.5=mild functional limitation; 0.5-1=moderate functional limitation; more than 1=significant functional limitation. V3, CV, and the change from V3 to CV was determined.
Measured: Visit 3 (7 months) and CV (4 weeks after GC-free status, maximum of 24 weeks after V3)
VAS-Physician's Global Assessment of Disease Activity (GDA) During the Interventional Phase
Physician's were asked to determine the overall GDA for each participant using a 100-mm VAS, where 0=no disease activity and 100=maximum disease activity. The physician marked the line corresponding to their assessment and the distance from the left edge was measured. V3, CV, and the change from V3 to CV was determined.
Measured: V3 (7 months) and CV (4 weeks after GC-free status, maximum of 24 weeks after V3)
VAS for Pain (VAS-Pain) During the Interventional Phase
Participants were asked to mark the line corresponding to the intensity of their pain on a 100-mm VAS, where 0=no pain and 100=worst possible pain. The distance from the left edge was measured. Change = V3 mean minus CV mean.
Measured: V3 (7 months) and CV (4 weeks after GC-free status, maximum of 24 weeks after V3)
SJC and TJC During the Interventional Phase
TJC and SJC were assessed for 28 joints. An assessment of 28 joints for swelling and tenderness was made. Joints were assessed and classified as swollen (1)/not swollen (0) and tender (1)/not tender (0) by pressure and joint manipulation on physical examination for a total score range of 0-28. Higher scores indicated greater disease activity (tenderness/swelling). V3, CV, and the change from V3 to CV was determined.
Measured: V3 (7 months) and CV (4 weeks after GC-free status, maximum of 24 weeks after V3)
Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score During the Interventional Phase
FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (not at all) to 4 (very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-F score for a total possible score of 0 (worse score) to 52 (better score). V3, CV, and the change from V3 to CV was determined.
Measured: V3 (7 months) and CV (4 weeks after GC-free status, maximum of 24 weeks after V3)
Short-Form 36 (SF-36) Mental Component Score (MCS) and Physical Component Score (PCS) During the Interventional Phase
36-Item Short-Form Health Survey (SF-36) is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects can also be summarized as physical and mental component scores (PCS and MCS). Total of 11 variables were analyzed (8 subscales, 2 composite subscales and Question 2 "how would you rate your health in general now?" (range 1= better, 5= worst). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Higher scores reflect higher quality of life. V3, CV, and the change from V3 to CV was determined.
Measured: V3 (7 months) and CV (4 weeks after GC-free status, maximum of 24 weeks after V3)
SF-36 Subscale Scores During the Interventional Phase
SF-36 is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects can also be summarized as physical and mental component scores (PCS and MCS). Total of 11 variables were analyzed (8 subscales, 2 composite subscales and Question 2 "how would you rate your health in general now?" (range 1= better, 5= worst). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Higher scores reflect higher quality of life. V3, CV, and the change from V3 to CV was determined.
Measured: V3 (7 months) and CV (4 weeks after GC-free status, maximum of 24 weeks after V3)
CDAI Score During the Interventional Phase
The CDAI is the numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGA and PGA assessed on 0-100 mm VAS; higher scores=greater affection due to disease activity. CDAI total score=0-76. CDAI ≤2.8=disease remission, >2.8 to 10=LDA, >10 to 22=moderate disease activity, and >22=high disease activity. V3, CV, and the change from V3 to CV was determined.
Measured: V3 (7 months) and CV (4 weeks after GC-free status, maximum of 24 weeks after V3)
Percentage of Participants With LDA or Remission During the Interventional Phase Assessed Using CDAI
The CDAI is the numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGA and PGA assessed on 0-100 mm VAS; higher scores=greater affection due to disease activity. CDAI total score=0-76. CDAI ≤2.8=disease remission and >2.8 to 10=LDA.
Measured: Visits 3 (7 months), 4 (8 months), 5 (9 months), 6 (10 months), 7 (11 months), 8 (12 months), and 9 (24 weeks after V3) or CV (4 weeks after GC-free status, maximum of 24 weeks after V3)
Percentage of Participants With LDA or Remission During the Interventional Phase Assessed Using DAS28-CRP
DAS28 calculated from the number of swollen joints (SJC) and tender joints (TJC) using the 28 joint count, the CRP and PtGA of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28-CRP ≤3.2 and oral GC intake with MP equivalent dose of ≥1 mg and ≤20 mg/day=LDA; DAS28 <2.6 = remission.
Measured: Visits 3 (7 months), 4 (8 months), 5 (9 months), 6 (10 months), 7 (11 months), 8 (12 months), 9 (24 weeks after V3) or CV (4 weeks after GC-free status, maximum of 24 weeks after V3)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Oct 2010 (estimated)
- Study startJan 2011
- Primary completionMar 2013
- Study completionMar 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Rheumatoid ArthritisStudies of the same condition, open and under way.
- More trials run by Hoffmann-La RocheThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 68 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hoffmann-La Roche
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Trials, Study director, Hoffmann-La Roche
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01219933
- Sponsor's protocol ID
- ML25252
- Other IDs
- 2010-019694-15
- Status last verified
- Jan 2015
- First submitted
- 11 Oct 2010
- Last updated
- 19 Jan 2015
- Results posted
- Yes, on ClinicalTrials.gov
Study at a glance
From the registry record, last updated by the sponsor on 19 Jan 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open-label, Single-arm Study to Describe Glucocorticoid Use in Rheumatoid Arthritis Patients Treated With Tocilizumab in Daily Clinical Practice and to Evaluate Systematic Glucocorticoid Dose Reduction Once Low Disease Activity is Reached (ACT-ALONE)
- ClinicalTrials.gov ID
- NCT01219933
- Acronym / sponsor ID
- ML25252
- Conditions
- Rheumatoid Arthritis
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 68 participants (actual)
- Lead sponsor
- Hoffmann-La RocheIndustry (pharma, biotech, devices)
- Study start
- Jan 2011
- Primary completion
- Mar 2013 (actual)
- Study completion
- Mar 2013 (actual)
- First posted
- 13 Oct 2010 (estimated)
- Results
- Posted 19 Jan 2015
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This open-label, single-arm study will assess the use of glucocorticoids (GC) in daily clinical practice and will evaluate the dose reduction of glucocorticoids once low disease activity is achieved in patients with rheumatoid arthritis tre ated with GC and background RoActemra/Actemra (tocilizumab) 8mg/kg intravenously every 4 weeks. In the non-interventional phase, the use of GC in daily clinical Belgian practice will be evaluated and described. This period of maximum 6 mont hs will allow those patients to obtain the inclusion criteria for the secondary interventional phase. In the interventional phase, a systematic GC dose reductio n schedule will be evaluated in patients having achieved low disease activity wh ile receiving the same background therapy with RoActemra/Actemra 8 mg/kg. Methyl prednisolone will be given from a starting dose of >/= 1 mg to </=20 mg orally d aily and will be tapered down. The anticipated study duration is up to 13 months
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| 1 | Experimental | Drug: methylprednisolone, Drug: tocilizumab [RoActemra/Actemra] |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Non-interventional phase
- Adult patients, >/=18 years of age
- Moderate to severe active rheumatoid arthritis defined as Disease Activity Score using 28-joint count (DAS28) >/=5.1
- Patients with inadequate clinical response to a current treatment with 2 or more non-biologic disease-modifying anti-rheumatic drugs (DMARDs), one of them being methotrexate (MTX) optimally administered during a period of more than 3 months or inadequate response to a current anti-TNF therapy
- Current use of oral glucocorticoids started at least 4 weeks prior to enrolment Interventional phase
Key exclusion criteria (4 listed)
- Non-interventional \& interventional phase
- Rheumatic autoimmune disease other than rheumatoid arthritis, or significant systemic involvement secondary to rheumatoid arthritis
- Functional class IV as defined by the American College of Rheumatology (ACR) Classification of Functional Status in rheumatoid arthritis
- Prior history or current inflammatory joint disease other than rheumatoid arthritis (e.g. gout)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| methylprednisolonestarting dose >/= 1 mg and </= 20 mg orally daily, according to dose-reduction schedule | Drug | 1 |
| tocilizumab [RoActemra/Actemra]background therapy: 8 mg/kg iv every 4 weeks | Drug | 1 |
Primary outcome
Median GC Dose Taken During the Noninterventional Phase
Time frame: V1 and V2 (up to 6 months after V1)
During the noninterventional phase of the study participants received GC as prescribed by the physician. Doses of all GC administered are expressed as MP equivalents.
Number of Participants With GC Switches During the Noninterventional Phase
Time frame: V1 and V2 (up to 6 months after V1)
During the noninterventional phase of the study, once LDA was achieved, GC was switched to MP tablets.
Type of GC Taken at the End of the Noninterventional Phase
Time frame: V1 and V2 (up to 6 months after V1)
During the noninterventional phase of the study participants received GC as prescribed by the physician.
Percentage of Participants in the Interventional Phase Who Achieved LDA and Discontinued Oral GC Within 20 Weeks
Time frame: Visits 3 (7 months), 4 (8 months), 5 (9 months), 6 (10 months), 7 (11 months), and 8 (12 months)
The percentage of participants with rheumatoid arthritis (RA) with LDA was defined as DAS28 ≤3.2, able to discontinue oral GC within 20 weeks and at the latest at V8, confirmed at the Consolidation Visit without loss of clinical response defined as DAS28 (CRP) >3.2.
29 secondary outcomes
Percentage of Participants Able to Acheive LDA Assessed Using DAS28 While Receiving Oral GC on Background Tocilizumab Treatment During the Noninterventional Phase
Time frame: V1 and V2 (up to 6 months after V1)
Percentage of Participants Acheiving Remission Assessed Using DAS28 While Receiving Oral GC on Background TocilizumabTreatment During the Noninterventional Phase
Time frame: V1 and V2 (up to 6 months after V1)
Percentage of Participants With Erosions During the NonInterventional Phase
Time frame: V1 and V2 (up to 6 months after V1)
Number of Erosions During the NonInterventional Phase
Time frame: V1 and V2 (up to 6 months after V1)
Percentage of Participants Positive for Rheumatoid Factor (RF) During the Noninterventional Phase
Time frame: V1 and V2 (up to 6 months after V1)
Percentage of Participants Positive for Anti-cyclic Citrullinated Peptide (Anti-CCP) Antibody During the Noninterventional Phase
Time frame: V1 and V2 (up to 6 months after V1)
Health Assessment Questionnaire Disability Index (HAQ-DI) During the Noninterventional Phase
Time frame: V1 and V2 (up to 6 months after V1)
DAS28-CRP During the Noninterventional Phase
Time frame: V1 and V2 (up to 6 months after V1)
DAS28-ESR During the Noninterventional Phase
Time frame: V1 and V2 (up to 6 months after V1)
Clinical Disease Activity Index (CDAI) During the Noninterventional Phase
Time frame: V1 and V2 (up to 6 months after V1)
Median Time Interval Between V1 and V2
Time frame: V1 and V2 (up to 6 months after V1)
Median Dose of Tocilizumab During the Noninterventional Phase
Time frame: V1 and V2 (up to 6 months after V1)
Number of Participants With Changes in Tocilizumab Dose During the Noninterventional Phase
Time frame: V1 and V2 (up to 6 months after V1)
Percentage of Participants With Changes in RA Treatment During the Noninterventional Phase
Time frame: V1 and V2 (up to 6 months after V1)
Percentage of Participants Able to Start the GC Reduction Phase at V3
Time frame: V3 (7 months)
Percentage of Participants Able to Reduce Oral GCs by ≥50 Percent (%) During the Interventional Phase by V9
Time frame: V9 (24 weeks after V3)
Percentage of Participants Able to Discontinue GCs During the Interventional Phase by V9
Time frame: V9 (24 weeks after V3)
Time-Averaged GC Dose Changes During the Interventional Phase
Time frame: V3 (7 months) and CV (4 weeks after GC-free status, maximum of 24 weeks after V3)
DAS28-CRP During the Interventional Phase
Time frame: V3 (7 months) and CV (4 weeks after GC-free status, maximum of 24 weeks after V3)
HAQ-DI During the Interventional Phase
Time frame: Visit 3 (7 months) and CV (4 weeks after GC-free status, maximum of 24 weeks after V3)
VAS-Physician's Global Assessment of Disease Activity (GDA) During the Interventional Phase
Time frame: V3 (7 months) and CV (4 weeks after GC-free status, maximum of 24 weeks after V3)
VAS for Pain (VAS-Pain) During the Interventional Phase
Time frame: V3 (7 months) and CV (4 weeks after GC-free status, maximum of 24 weeks after V3)
SJC and TJC During the Interventional Phase
Time frame: V3 (7 months) and CV (4 weeks after GC-free status, maximum of 24 weeks after V3)
Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score During the Interventional Phase
Time frame: V3 (7 months) and CV (4 weeks after GC-free status, maximum of 24 weeks after V3)
Short-Form 36 (SF-36) Mental Component Score (MCS) and Physical Component Score (PCS) During the Interventional Phase
Time frame: V3 (7 months) and CV (4 weeks after GC-free status, maximum of 24 weeks after V3)
SF-36 Subscale Scores During the Interventional Phase
Time frame: V3 (7 months) and CV (4 weeks after GC-free status, maximum of 24 weeks after V3)
CDAI Score During the Interventional Phase
Time frame: V3 (7 months) and CV (4 weeks after GC-free status, maximum of 24 weeks after V3)
Percentage of Participants With LDA or Remission During the Interventional Phase Assessed Using CDAI
Time frame: Visits 3 (7 months), 4 (8 months), 5 (9 months), 6 (10 months), 7 (11 months), 8 (12 months), and 9 (24 weeks after V3) or CV (4 weeks after GC-free status, maximum of 24 weeks after V3)
Percentage of Participants With LDA or Remission During the Interventional Phase Assessed Using DAS28-CRP
Time frame: Visits 3 (7 months), 4 (8 months), 5 (9 months), 6 (10 months), 7 (11 months), 8 (12 months), 9 (24 weeks after V3) or CV (4 weeks after GC-free status, maximum of 24 weeks after V3)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Jan 2015.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Rheumatoid Arthritis
RecruitingPhase 2
Study of PTC844 in Participants With Active Rheumatoid Arthritis
Rheumatoid Arthritis
Not yet recruitingPhase 1
An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE)
Rheumatoid Arthritis and Systemic Lupus Erythematosus
Not yet recruitingPhase 1
R-2487 in Patients With Sjogren's Syndrome (SjD)
Sjogren's Syndrome, Sjögren
RecruitingPhase 1
A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body
Rheumatoid Arthritis, Systemic Lupus Erythematosus
Active, not recruitingPhase 2
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clinical Trials study director
Hoffmann-La Roche
16 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing methylprednisolone and tocilizumab [RoActemra/Actemra] in people with Rheumatoid Arthritis, run by Hoffmann-La Roche at 16 sites in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Jan 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 16 sites in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 19 Jan 2015). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Median GC Dose Taken During the Noninterventional Phase (time frame: V1 and V2 (up to 6 months after V1)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Jan 2015.